| KPI | [EUR m] | Q2 2024 | FY 2024 | Q1 2025 | Q2 2025 E | FY 2025 E | FY 2026 E | FY 2027 E | FY 2028 E |
|---|---|---|---|---|---|---|---|---|---|
| Custom Solutions; Sales | Number of Estimates | 4 | 5 | 5 | 5 | 4 | |||
| Custom Solutions; Sales | Highest | 1,451.0 | 5,760.0 | 5,998.0 | 6,298.0 | 6,581.0 | |||
| Custom Solutions; Sales | Average | 1,406.0 | 5,630.9 | 5,865.2 | 6,111.1 | 6,387.8 | |||
| Custom Solutions; Sales | Consensus (Median) | 1,472.0 | 5,737.0 | 1,426.0 | 1,408.7 | 5,654.7 | 5,918.1 | 6,178.0 | 6,487.4 |
| Custom Solutions; Sales | Lowest | 1,355.8 | 5,481.8 | 5,665.5 | 5,837.1 | 5,995.4 | |||
| Additives; Sales | Number of Estimates | 2 | 3 | 3 | 3 | 3 | |||
| Additives; Sales | Highest | 980.0 | 3,865.0 | 4,025.0 | 4,216.0 | 4,450.0 | |||
| Additives; Sales | Average | 931.3 | 3,738.8 | 3,865.4 | 3,998.9 | 4,142.0 | |||
| Additives; Sales | Consensus (Median) | 1,017.0 | 3,908.0 | 973.0 | 931.3 | 3,791.0 | 3,904.0 | 4,022.0 | 4,142.0 |
| Additives; Sales | Lowest | 882.6 | 3,560.3 | 3,667.1 | 3,758.8 | 3,834.0 | |||
| Health & Care; Sales | Number of Estimates | 2 | 3 | 3 | 3 | 3 | |||
| Health & Care; Sales | Highest | 473.2 | 1,921.5 | 2,016.0 | 2,157.0 | 2,308.0 | |||
| Health & Care; Sales | Average | 472.1 | 1,900.2 | 1,995.8 | 2,105.8 | 2,200.1 | |||
| Health & Care; Sales | Consensus (Median) | 455.0 | 1,829.0 | 453.0 | 472.1 | 1,895.0 | 1,998.4 | 2,082.0 | 2,161.4 |
| Health & Care; Sales | Lowest | 471.0 | 1,884.0 | 1,973.0 | 2,078.3 | 2,131.0 | |||
| Custom Solutions; Adjusted EBITDA | Number of Estimates | 4 | 5 | 5 | 5 | 4 | |||
| Custom Solutions; Adjusted EBITDA | Highest | 424.5 | 1,159.5 | 1,220.1 | 1,286.6 | 1,346.8 | |||
| Custom Solutions; Adjusted EBITDA | Average | 266.5 | 980.8 | 1,047.2 | 1,126.4 | 1,177.7 | |||
| Custom Solutions; Adjusted EBITDA | Consensus (Median) | 281.0 | 978.0 | 256.0 | 255.6 | 1,020.0 | 1,107.0 | 1,174.0 | 1,277.0 |
| Custom Solutions; Adjusted EBITDA | Lowest | 130.1 | 693.1 | 734.7 | 771.4 | 810.0 | |||
| Custom Solutions; Adjusted EBITDA margin in % | Number of Estimates | 4 | 5 | 5 | 5 | 4 | |||
| Custom Solutions; Adjusted EBITDA margin in % | Highest | 31.3 | 21.2 | 21.5 | 22.0 | 22.5 | |||
| Custom Solutions; Adjusted EBITDA margin in % | Average | 19.1 | 17.4 | 17.9 | 18.5 | 18.5 | |||
| Custom Solutions; Adjusted EBITDA margin in % | Consensus (Median) | 19.1 | 17.0 | 18.0 | 17.9 | 17.7 | 18.5 | 19.2 | 19.6 |
| Custom Solutions; Adjusted EBITDA margin in % | Lowest | 9.2 | 12.4 | 12.4 | 12.4 | 12.4 | |||
| Advanced Technologies; Sales | Number of Estimates | 4 | 5 | 5 | 5 | 4 | |||
| Advanced Technologies; Sales | Highest | 1,549.5 | 6,426.0 | 6,619.0 | 6,818.0 | 7,022.0 | |||
| Advanced Technologies; Sales | Average | 1,525.6 | 6,228.9 | 6,415.4 | 6,628.8 | 6,929.7 | |||
| Advanced Technologies; Sales | Consensus (Median) | 1,533.0 | 6,089.0 | 1,601.0 | 1,541.1 | 6,168.0 | 6,332.6 | 6,649.2 | 6,939.3 |
| Advanced Technologies; Sales | Lowest | 1,470.7 | 5,974.1 | 6,249.2 | 6,374.1 | 6,818.0 | |||
| Organics; Sales | Number of Estimates | 2 | 3 | 3 | 3 | 3 | |||
| Organics; Sales | Highest | 415.0 | 1,732.0 | 1,784.0 | 1,847.0 | 1,917.0 | |||
| Organics; Sales | Average | 326.4 | 1,497.7 | 1,553.4 | 1,596.5 | 1,633.8 | |||
| Organics; Sales | Consensus (Median) | 441.0 | 1,665.0 | 426.0 | 326.4 | 1,655.0 | 1,759.0 | 1,837.0 | 1,892.0 |
| Organics; Sales | Lowest | 237.8 | 1,106.1 | 1,117.2 | 1,105.4 | 1,092.3 | |||
| Inorganics; Sales | Number of Estimates | 2 | 3 | 3 | 3 | 3 | |||
| Inorganics; Sales | Highest | 851.8 | 3,314.5 | 3,414.0 | 3,516.4 | 3,621.9 | |||
| Inorganics; Sales | Average | 739.9 | 2,759.2 | 2,861.0 | 2,965.5 | 3,064.6 | |||
| Inorganics; Sales | Consensus (Median) | 641.0 | 2,490.0 | 621.0 | 739.9 | 2,490.0 | 2,604.0 | 2,738.0 | 2,851.0 |
| Inorganics; Sales | Lowest | 628.0 | 2,473.0 | 2,565.0 | 2,642.0 | 2,721.0 | |||
| Animal Nutrition; Sales | Number of Estimates | 2 | 3 | 3 | 3 | 3 | |||
| Animal Nutrition; Sales | Highest | 505.0 | 2,205.0 | 2,271.0 | 2,339.0 | 2,409.0 | |||
| Animal Nutrition; Sales | Average | 482.4 | 2,081.3 | 2,084.3 | 2,145.0 | 2,213.9 | |||
| Animal Nutrition; Sales | Consensus (Median) | 450.0 | 1,934.0 | 554.0 | 482.4 | 2,040.0 | 2,071.9 | 2,126.1 | 2,182.8 |
| Animal Nutrition; Sales | Lowest | 459.8 | 1,999.0 | 1,910.0 | 1,970.0 | 2,050.0 | |||
| Advanced Technologies; Adjusted EBITDA | Number of Estimates | 2 | 5 | 5 | 5 | 4 | |||
| Advanced Technologies; Adjusted EBITDA | Highest | 277.0 | 1,055.0 | 1,135.0 | 1,256.0 | 1,329.0 | |||
| Advanced Technologies; Adjusted EBITDA | Average | 275.6 | 940.2 | 994.4 | 1,054.9 | 1,101.9 | |||
| Advanced Technologies; Adjusted EBITDA | Consensus (Median) | 267.0 | 1,023.0 | 291.0 | 275.6 | 1,026.6 | 1,040.8 | 1,090.8 | 1,116.4 |
| Advanced Technologies; Adjusted EBITDA | Lowest | 274.3 | 723.8 | 767.2 | 805.6 | 845.9 | |||
| Advanced Technologies; Adjusted EBITDA margin in % | Number of Estimates | 2 | 5 | 5 | 5 | 4 | |||
| Advanced Technologies; Adjusted EBITDA margin in % | Highest | 17.9 | 17.1 | 18.1 | 19.2 | 19.5 | |||
| Advanced Technologies; Adjusted EBITDA margin in % | Average | 17.9 | 15.1 | 15.5 | 15.9 | 15.9 | |||
| Advanced Technologies; Adjusted EBITDA margin in % | Consensus (Median) | 17.4 | 16.8 | 18.2 | 17.9 | 16.0 | 16.7 | 17.1 | 16.0 |
| Advanced Technologies; Adjusted EBITDA margin in % | Lowest | 17.9 | 12.1 | 12.1 | 12.1 | 12.1 | |||
| Infrastructure / Other incl. C4; Sales | Number of Estimates | 7 | 9 | 9 | 9 | 7 | |||
| Infrastructure / Other incl. C4; Sales | Highest | 934.3 | 3,331.0 | 3,226.2 | 3,258.5 | 3,291.1 | |||
| Infrastructure / Other incl. C4; Sales | Average | 799.5 | 2,848.4 | 2,825.2 | 2,854.6 | 3,075.5 | |||
| Infrastructure / Other incl. C4; Sales | Consensus (Median) | 925.0 | 3,331.0 | 749.0 | 747.2 | 2,931.0 | 2,967.2 | 3,010.8 | 3,071.0 |
| Infrastructure / Other incl. C4; Sales | Lowest | 727.2 | 1,148.5 | 1,171.5 | 1,194.9 | 2,787.5 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA | Number of Estimates | 7 | 9 | 9 | 9 | 7 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA | Highest | 18.7 | 64.3 | 91.1 | 125.6 | 100.5 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA | Average | 9.1 | 44.0 | 56.3 | 68.2 | 71.5 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA | Consensus (Median) | 31.0 | 63.0 | 13.0 | 8.0 | 52.3 | 62.0 | 65.0 | 69.6 |
| Infrastructure / Other incl. C4; Adjusted EBITDA | Lowest | 5.0 | -15.0 | -15.0 | -15.0 | 43.0 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA margin in % | Number of Estimates | 7 | 9 | 9 | 9 | 7 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA margin in % | Highest | 2.0 | 2.0 | 3.1 | 4.1 | 3.1 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA margin in % | Average | 1.1 | 1.3 | 1.8 | 2.1 | 2.3 | |||
| Infrastructure / Other incl. C4; Adjusted EBITDA margin in % | Consensus (Median) | 3.4 | 1.9 | 1.7 | 1.1 | 1.8 | 2.0 | 2.3 | 2.4 |
| Infrastructure / Other incl. C4; Adjusted EBITDA margin in % | Lowest | 0.7 | -1.3 | -1.3 | -1.3 | 1.3 |
This document has been issued by Vara Research GmbH for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. The company did not participate in the compilation of the estimates and it does not endorse them. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Vara Research GmbH gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness.
